NCT00491309

Brief Summary

In Patients with rheumatic disease exercise training is a well established element of therapy. In contrast patients with severe pulmonary hypertension are advised to avoid physical exertion and must not perform exercise training. This study aims to evaluate the effectivity and safety of a low-dose training program in patients with pulmonary hypertension and rheumatic disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
45

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 25, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 26, 2007

Completed
4 years until next milestone

Study Start

First participant enrolled

July 1, 2011

Completed
12.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

July 14, 2022

Status Verified

July 1, 2022

Enrollment Period

12.4 years

First QC Date

June 25, 2007

Last Update Submit

July 12, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in the 6-minute walking distance

    after 3 weeks and after 15 weeks compared to baseline.

  • Quality of life (SF-36)

    baseline and 15 weeks

Secondary Outcomes (6)

  • change in inflammatory parameters (BKS, CRP, Leucocytes), change in inflammatory cytokines (TNF-α), change in parameters of the vascular endothelium (Endothelin, PDGF, VEGF), and endothelial progenitor cells

    baseline and 15 weeks

  • Physical capacity in the cardiopulmonary exercise testing (Watt)

    baseline, 3 weeks, 15 weeks

  • change of peak oxygen consumption and other parameters of cardiopulmonary exercise testing.

    baseline, 3 weeks, 15 weeks

  • hemodynamic parameters: dimension and pump function of the right and the left ventricle.

    baseline, 15 weeks

  • change in systolic pulmonary arterial pressure at rest and during exercise

    baseline, 3 weeks, 15 weeks

  • +1 more secondary outcomes

Study Arms (2)

exercise training group

ACTIVE COMPARATOR

exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)

Behavioral: exercise training

Control group without exercise training

NO INTERVENTION

continuation of sedentary lifestyle without advice for specific exercise training

Interventions

exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)

exercise training group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Informed consent
  • Men and women 18 - 80 years
  • Diagnosed rheumatic disease: rheumatoid arthritis, Collagenosis (Systemic Lupus Erythematodes, Systemic Sclerosis, Sjögren-Syndrome, Sharp-Syndrome, Crest-Syndrome, Mixed connective tissue disease)
  • Symptomatic PAH (WHO- functional class II-IV) invasively diagnosed by right heart catheterisation
  • Mean pulmonary artery pressure (mPAP) \> 25 mmHg
  • Pulmonary capillary wedge pressure (PCWP) \> 15 mmHg
  • Pulmonary vascular resistance (PVR) at baseline \>320 dyn.sec/cm5 patients under optimized medical treatment since at least 2 ½ months

You may not qualify if:

  • Other forms of PAH.
  • Pregnancy or lactation
  • Change in medication during the last 2 ½ months
  • Patients with signs of right heart decompensation
  • Severe impairment of walking
  • Unclear diagnosis
  • No invasive diagnosis of PH
  • Acute illness, infection, fever
  • Severe lung disease with FEV1 \<50% and TLC\< 70% below reference

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thoraxclinic at the University Hospital Heidelberg

Heidelberg, Baden-Wurttemberg, 69126, Germany

RECRUITING

Related Publications (1)

  • Grunig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, Fiehn C, Stockl F, Prange F, Staehler G, Reichenberger F, Tiede H, Halank M, Seyfarth HJ, Wagner S, Nagel C. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther. 2012 Jun 18;14(3):R148. doi: 10.1186/ar3883.

MeSH Terms

Conditions

Hypertension, PulmonaryConnective Tissue Diseases

Interventions

Exercise

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesHypertensionVascular DiseasesCardiovascular DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Ekkehard Gruenig, MD

    Thoraxclinic at the University Hospital Heidelberg

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. med. Ekkehard Grünig

Study Record Dates

First Submitted

June 25, 2007

First Posted

June 26, 2007

Study Start

July 1, 2011

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

July 14, 2022

Record last verified: 2022-07

Locations